CJC-1295 Ipamorelin Protocol: Dosage, Timing, and Stacking Explained

A CJC-1295 ipamorelin protocol is a stacking schedule that pairs a growth hormone-releasing hormone (GHRH) analog with a selective ghrelin-receptor agonist in order to amplify natural growth hormone pulses. Most versions use 100-200 mcg of each peptide, injected subcutaneously once or twice per day, with doses timed around sleep and sometimes around training. Neither peptide is FDA-approved for human use in the United States, so everything below is educational and framed for research rather than self-treatment.

How the CJC-1295 and Ipamorelin Stack Works

CJC-1295 is a modified GHRH analog. It binds GHRH receptors in the pituitary and signals the gland to release growth hormone. Ipamorelin belongs to a different class: it mimics ghrelin at the GHS-R1a receptor, which triggers a separate GH release pathway.

Because the two compounds act on different receptors, they are usually described as complementary rather than redundant. Anyone asking what is cjc-1295 ipamorelin is really asking how that pairing works: one peptide sets the signal, the other amplifies it.

Ipamorelin is generally considered the most selective of the common ghrelin mimetics. Research literature reports minimal effect on cortisol, prolactin, and appetite compared with older compounds such as GHRP-6, which is one reason it became the default partner for GHRH analogs.

Typical Dosage and Timing

There is no standard, approved cjc-1295 ipamorelin dosage protocol, and published human data are thin. What circulates online are community conventions drawn from early animal research, small studies, and anecdotal reports.

Common Research Dosing

• CJC-1295 without DAC: 100-200 mcg per injection, 1-3 times daily
• CJC-1295 with DAC: 1-2 mg per week, often split into two injections
• Ipamorelin: 100-300 mcg per injection, 1-3 times daily
• Cycle length: commonly 8-12 weeks on, followed by a break

Doses are usually kept low because the goal is to mimic a pulse, not to create a continuous signal. Injecting on an empty stomach is frequently recommended, since food and insulin can blunt the growth hormone response.

Timing and Frequency

Most discussion around the best time to take cjc 1295 ipamorelin centers on pre-sleep dosing, because the largest natural GH pulse occurs during the first hours of deep sleep. A second dose is sometimes placed pre-workout or immediately after waking.

Spacing doses three to four hours apart is a common practice. Stacking two injections within minutes of each other is not.

CJC-1295 With DAC vs Without DAC

The DAC version carries a drug affinity complex that binds albumin and extends activity for days. The non-DAC version, often labeled Mod GRF (1-29), clears quickly and produces a sharper, more physiological pulse.

A cjc-1295 no dac ipamorelin protocol is the more popular pairing among researchers, because both peptides then rise and fall on a similar timescale. The DAC version is typically reserved for once- or twice-weekly schedules.

CJC-1295/Ipamorelin vs Tesamorelin

Tesamorelin is a GHRH analog as well, but it is the only peptide in this group with FDA approval, and that approval is narrow: visceral fat reduction in HIV-associated lipodystrophy.

When people compare cjc-1295 ipamorelin vs tesamorelin, the practical differences come down to approval status, cost, and target outcome. Tesamorelin has far stronger human trial data for visceral fat, while the CJC-1295 and ipamorelin stack has more community use for recovery and body composition goals.

A frequent question is whether you can take tesamorelin and cjc-1295 together. Because both act on the same GHRH receptor, combining them is generally viewed as redundant rather than additive, and there is no studied human data on the combination.

Adding AOD-9604, IGF-1 LR3, and Other Peptides

Some researchers layer a fat-loss fragment or a downstream growth factor on top of the base stack. A cjc 1295 ipamorelin aod 9604 combination is one example, and IGF-1 LR3 is another, although IGF-1 LR3 acts downstream of growth hormone entirely and carries its own risk profile.

Every addition multiplies variables. More compounds mean more injection sites, more potential side effects, and more difficulty attributing any result to a specific peptide.

Beginners are generally advised to research one compound at a time before considering any stack.

Safety, Side Effects, and Legal Status

CJC-1295 and ipamorelin are research chemicals, not approved medicines. Buying them from unregulated vendors means no guarantee of purity, accurate dosing, or sterility.

Reported side effects in anecdotal accounts include injection-site irritation, water retention, tingling in the hands, headaches, and fatigue. Because these peptides raise growth hormone, long-term supraphysiologic exposure raises theoretical concerns about insulin resistance, edema, and unwanted tissue growth.

Anyone considering use should speak with a licensed healthcare professional first. People with a history of cancer, diabetes, or pituitary disease should avoid growth hormone-stimulating compounds entirely.